The Friday 5 from Practical Cardiology is a list composed by the Practical Cardiology editorial staff aimed at highlighting relevant coverage of news in cardiovascular medicine.
Every Friday, Practical Cardiology provides a curated list of 5 articles focused or related to a particular topic. This week, the Friday 5 from Practical Cardiology highlights the latest edition of Inside Cardiology, which features a 5-part panel discussion with Practical Cardiology Editorial Advisory Board members Guy Mintz, MD, Lucia Novak, CRNP, and Brett Nowlan, MD.
The USPSTF has released a recommendation statement related to hypertension screenings among adults without known hypertension.
A new analysis of claims data performed by clinicians at Penn Medicine suggests less than 1% of patients with ASCVD initiated therapy with a PCKS9 inhibitor from 2015-2019.
Check out the latest coverage from the annual Society for Cardiovascular Angiography and Interventions 2021 Virtual Scientific Sessions.
An analysis comparing a national registry against ISCHEMIA enrollment criteria suggests trial eligibility represents less than 2% of all patients undergoing PCI and less than a third of patients undergoing PCI with stable ischemic heart disease.
An SCAI 2021 analysis of more than 4k patients with characteristics similar to those included in the TWILIGHT trial indicates extended-duration DAPT, defined as a duration of more than 12 months post-PCI, was a more efficacious approach than short-term DAPT in this patient population.